Taurine in Periodontitis and Aging
The Role of Taurine in Periodontitis and Aging: a Preliminary Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Unkapani
-
Istanbul, Unkapani, Turkey
- Istanbul Medipol University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Exclusion Criteria:
- ages 18-25 or 45-64
- use of antibiotics, anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, or anticoagulants within the last 6 months
- presence of diabetes, rheumatoid arthritis, or other systemic conditions such as cardiovascular, renal, hepatic, and neurodegenerative disorders
- pregnancy or lactation
- alcoholism
- smoking
- nonsurgical periodontal treatment in the past 6 months or surgical treatment in the past 12 months
- having less than 20 natural teeth, excluding third molars
- use of orthodontic appliances
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Young (25-44 years) with a healthy periodontium
|
Saliva, serum and periodontal indexes were obtained from patients
Other Names:
|
|
Experimental: young (25-44 years) with Periodontitis
|
Saliva, serum and periodontal indexes were obtained from patients
Other Names:
|
|
Experimental: Old (≥65 years) with a healthy periodontium
|
Saliva, serum and periodontal indexes were obtained from patients
Other Names:
|
|
Experimental: Old (≥65 years) with Periodontitis
|
Saliva, serum and periodontal indexes were obtained from patients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Taurine
Time Frame: 12 Weeks
|
Taurine levels in saliva and serum were measured
|
12 Weeks
|
|
SIRT1
Time Frame: 12 Weeks
|
SIRT1 levels in saliva and serum were measured
|
12 Weeks
|
|
TNF-α
Time Frame: 12 Weeks
|
TNF-α levels in saliva and serum were measured
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.